Data Analysis Yields Insights Into Medical Cannabis Use, Efficacy
June 21st, 2021
App, Exclusive, News, Top Story
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. Every major professional sport is undergoing an analytics revolution. Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications.
RYAH Group Inc. (CSE: RYAH) and its wholly-owned subsidiary RYAH Medtech are here to provide just the type of data and analysis needed to move the industry forward. With over 200,000 registered users providing input to the company’s patent-protected, AI-powered database, RYAH is providing unmatched insight into how, why, and how effectively medical cannabis is used.
How to Use the Data
RYAH publishes monthly reports discussing various topics arising from their analysis of the reams of data in its proprietary RYAH Cloud database, offering a glimpse of how the information can be used. The most recent one, from June 2021, takes a look at patients using cannabis to relieve pain. It’s an interesting analysis of who is using which strains to help treat which types of pain.
Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain. The company’s analysis of the collected data yielded several insights. Men were more likely than women to treat pain with cannabis. Indicas accounted for about 46% of use, sativas about 33%, and hybrids 21%. CBD-rich strains were generally preferred by all parties involved. The report even breaks down preferred strains by indication, including arthritis, headache/migraine, and inflammation.
The May 2021 report highlights medical cannabis use for the treatment of nausea, wasting syndrome, and cachexia (extreme weight loss and muscle wasting in the late stages of serious diseases like cancer, HIV or AIDS, COPD, kidney disease, and congestive heart failure). RYAH examined reporting from 17,313 such patients over the course of about 3 ½ years. Most of the data came from five states that list these indications as qualifying conditions for the use of medical cannabis. Imagine the amount of data that would be available from a much larger population sample.
Here, RYAH found that indica and indica-dominant strains were by far the preferred strain type, accounting for about 70% of use. The report further breaks down use by specific cultivars. Interestingly, the strains most highly rated for appetite stimulation were not the strains most commonly used by these patients. Women were slightly more likely than men to use cannabis for nausea, while the wasting syndrome and cachexia populations were tilted to men.
Advantages of Data, Macro, and Micro
Small sample size is really the bane of data analysis and can often result in wild assumptions that don’t pan out when tested in larger populations. If 40 people report their experiences in treating pain to their medical provider, that doctor does not have enough information to form generalized recommendations. But if that doctor has access to information from 40,000 patients it’s a different story. RYAH’s database provides that type of scale to all parties involved – patients, doctors, researchers, drug developers, growers, etc.
On the flip side, the company’s personalized app draws information from that large dataset and combines it with each patient’s individual experience to provide specific recommendations for that patient. The whole system is fueled by RYAH’s suite of smart dosing devices, including a patch, inhaler, and pen. The devices allow patients to measure and control their doses, something that is a huge challenge considering the variables and inconsistencies in the chemical makeup of cannabis plants.
Taking the doctor-patient use of RYAH devices one step further, organizations conducting clinical trials are finding value in the company’s offerings. RYAH Smart inhalers are being used in a huge clinical trial based in the UK. A major oncology clinic aims to explore the efficacy and safety of cannabis to treat patients suffering from chronic pain. Over a five year study, the clinic intends to work with tens of thousands of patients. RYAH will supply IoT-controlled Smart Inhalers with a fully customized software solution and direct API data integration with the clinic’s Electronic Health Record system. This means researchers will better protect participant privacy, mitigate the number of variables associated with cannabis consumption, and make scaling the trial relatively simple.
RYAH is providing large amounts of data to a medical cannabis industry in desperate need of just that sort of information. This data is used by patients and doctors to personalize and control treatments, by doctors and researchers to learn about the trends and realities of patient use, by growers to determine which strains are preferred by patients, and by clinical researchers to organize and inform their studies. RYAH recently went public on the Canadian Securities Exchange and is aggressively growing its reach and distribution in lockstep with the explosive growth of the cannabis industry in general. For cannabis, the time is now to establish widespread legitimacy, and data like RYAH’s is crucial to achieving that goal.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.